Alnylam Pharmaceuticals | ALNY - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amgen USD 1.6B 187M 2026-03
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
Moderna USD 955M 503M 2026-03
Neurocrine Biosciences USD 13.8M 3.8M 2026-03
Novartis USD 3.46B 83M 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.14B 618M 2026-03
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
Takeda JPY 560.54B 159.39B 2026-03
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 392.8M 73.2M 2026-03
Xencor USD 61.66M 50.95M 2025-06